Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Research analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Surmodics in a note issued to investors on Tuesday, April 9th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of ($0.23) per share for the quarter, up from their prior forecast of ($0.28). The consensus estimate for Surmodics' current full-year earnings is ($0.90) per share. Zacks Research also issued estimates for Surmodics' Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.22) EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at ($0.11) EPS and FY2026 earnings at $0.25 EPS.
A number of other research firms have also commented on SRDX. StockNews.com upgraded Surmodics from a "hold" rating to a "buy" rating in a research note on Thursday, December 14th. Needham & Company LLC restated a "buy" rating and issued a $47.00 price target on shares of Surmodics in a research report on Wednesday.
Read Our Latest Report on SRDX
Surmodics Price Performance
Shares of NASDAQ SRDX traded up $0.04 during midday trading on Thursday, reaching $27.68. The company's stock had a trading volume of 156,906 shares, compared to its average volume of 47,087. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.97 and a current ratio of 4.84. The company has a market cap of $394.16 million, a P/E ratio of 72.84 and a beta of 1.01. The business's 50 day moving average price is $30.00 and its two-hundred day moving average price is $32.06. Surmodics has a fifty-two week low of $16.79 and a fifty-two week high of $39.41.
Institutional Trading of Surmodics
Several large investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its stake in Surmodics by 305.8% during the third quarter. Tower Research Capital LLC TRC now owns 775 shares of the company's stock worth $25,000 after purchasing an additional 584 shares during the last quarter. UBS Group AG lifted its position in shares of Surmodics by 141.1% during the 3rd quarter. UBS Group AG now owns 2,290 shares of the company's stock worth $70,000 after buying an additional 1,340 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Surmodics during the 3rd quarter worth $87,000. Captrust Financial Advisors boosted its stake in Surmodics by 24.3% in the first quarter. Captrust Financial Advisors now owns 2,307 shares of the company's stock valued at $105,000 after buying an additional 451 shares in the last quarter. Finally, Citigroup Inc. grew its position in Surmodics by 1,023.0% in the second quarter. Citigroup Inc. now owns 4,144 shares of the company's stock valued at $130,000 after acquiring an additional 3,775 shares during the last quarter. Institutional investors and hedge funds own 96.63% of the company's stock.
About Surmodics
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Read More
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
